SchizophreniaPhase 2ERUDITENCT05182476
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
A Phase 2 study testing Luvadaxistat in people with Schizophrenia, run by Neurocrine Biosciences at 49 sites in 5 countries.
Trial summary
Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in participants with schizophrenia. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Schizophrenia
- What is being tested?
- Luvadaxistat
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 216 participants
- Where
- 49 sitesin 5 countries
- Study dates
- 7 Dec 2021to 14 Oct 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Participants must meet all of the following inclusion criteria:
- Completed written informed consent.
- Participant must be 18 to 50 years of age (inclusive) and able to comply with all protocol procedures.
- Diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
- The initial diagnosis of schizophrenia must be ≥1 year before screening.
- The participant is currently receiving a stable regimen of psychotropic medications.
Show all 9Show fewer
- Participant has stable symptomatology ≥3 months before the screening visit.
- The participant must have an adult informant.
- A body weight of at least 45 kilograms (kg) and a body mass index (BMI) of 18.0 to 45.0 kg/meter squared (m^2), inclusive.
Who cannot join
- Participants will be excluded from the study if they meet any of the following criteria:
- Pregnant or breastfeeding or plans to become pregnant during the study.
- Exhibit more than a minimal level of extrapyramidal signs/symptoms.
- Schizophrenia diagnosis occurred before 12 years of age.
- Lifetime diagnosis of schizoaffective disorder, bipolar disorder, or obsessive-compulsive disorder.
- Recent occurrence of panic disorder, depressive episode, or other comorbid psychiatric conditions.
Show all 10Show fewer
- Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property, or the participant has attempted suicide within 6 months before screening.
- Diagnosis of moderate or severe substance use disorder (with the exception of nicotine dependence) within 12 months prior to screening.
- Positive drug screen for disallowed substances.
- Any other medical or psychiatric condition or cognitive impairment that may interfere with study conduct or clinical assessments.
Trial locations and contacts
49 sites in 5 countries.
49 sites in 5 countries
United States33 sites
Neurocrine Clinical Site
Anaheim, California, 92805
Neurocrine Clinical Site
Ann Arbor, Michigan, 48105
Neurocrine Clinical Site
Atlanta, Georgia, 30338
Neurocrine Clinical Site
Aventura, Florida, 33180
Neurocrine Clinical Site
Bellflower, California, 90706
Neurocrine Clinical Site
Bentonville, Arkansas, 72712
Neurocrine Clinical Site
Bryant, Arkansas, 72022
Neurocrine Clinical Site
Cedarhurst, New York, 11516
Neurocrine Clinical Site
Chicago, Illinois, 60640
Neurocrine Clinical Site
DeSoto, Texas, 75115
Neurocrine Clinical Site
Flowood, Mississippi, 39232
Neurocrine Clinical Site
Garden Grove, California, 92845
Neurocrine Clinical Site
Glendale, California, 91206
Neurocrine Clinical Site
Houston, Texas, 77030
Neurocrine Clinical Site
Miami, Florida, 33016
Neurocrine Clinical Site
Miami, Florida, 33133
Neurocrine Clinical Site
Miami, Florida, 33144
Neurocrine Clinical Site
Miami, Florida, 33176
Neurocrine Clinical Site
New York, New York, 10032
Neurocrine Clinical Site
New York, New York, 10035
Neurocrine Clinical Site
Oceanside, California, 92056
Neurocrine Clinical Site
Okeechobee, Florida, 34972
Neurocrine Clinical Site
Pensacola, Florida, 32502
Neurocrine Clinical Site
Phoenix, Arizona, 85012
Neurocrine Clinical Site
Pico Rivera, California, 90660
Neurocrine Clinical Site
San Diego, California, 92102
Neurocrine Clinical Site
San Diego, California, 92103
Neurocrine Clinical Site
San Rafael, California, 94901
Neurocrine Clinical Site
St Louis, Missouri, 63128
Neurocrine Clinical Site
St Louis, Missouri, 63141
Neurocrine Clinical Site
Stanford, California, 94305
Neurocrine Clinical Site
Tampa, Florida, 33629
Neurocrine Clinical Site
Torrance, California, 90502
Bulgaria7 sites
Neurocrine Clinical Site
Pleven, 5800
Neurocrine Clinical Site
Plovdiv, 4004
Neurocrine Clinical Site
Sofia, 1000
Neurocrine Clinical Site
Sofia, 1113
Neurocrine Clinical Site
Sofia, 1408
Neurocrine Clinical Site
Sofia, 1510
Neurocrine Clinical Site
Sofia, 1680
Serbia5 sites
Neurocrine Clinical Site
Belgrade, 11000
Neurocrine Clinical Site
Gornja Toponica, 18202
Neurocrine Clinical Site
Kovin, 26220
Neurocrine Clinical Site
Kragujevac, 34000
Neurocrine Clinical Site
Niš, 18101
Czechia3 sites
Neurocrine Clinical Site
Pilsen, 301 00
Neurocrine Clinical Site
Prague, 100 00
Neurocrine Clinical Site
Prague, 160 00
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia, Followed by Open-Label Treatment
Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in participants with schizophrenia.
Read the detailed description
A Phase 2, randomized, double-blind, parallel, placebo-controlled study with a 6- or 12-month open-label extension. The study is designed to evaluate the efficacy, safety and tolerability, and pharmacokinetics (PK) of treatment with luvadaxistat when administered orally once daily as an adjunctive treatment on improving symptoms of cognitive impairment associated with schizophrenia (CIAS).
- Conditions
- Schizophrenia
- Being tested
- Placebo, Luvadaxistat
- Keywords
- Schizophrenia, Cognitive Impairment, Luvadaxistat, NBI-1065844, TAK-831, CIAS, BAC, ERUDITE, Neurocrine
- Medical subject headings
- Schizophrenia, Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Oral tablets
LuvadaxistatDrug
Also called NBI-1065844, TAK-831
Oral tablets
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Placebo daily Receives: Drug: Placebo |
| Luvadaxistat treatment schedule 1 | Experimental | Luvadaxistat daily Receives: Drug: Luvadaxistat |
| Luvadaxistat treatment schedule 2 | Experimental | Luvadaxistat daily Receives: Drug: Luvadaxistat |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BAC) Composite Score
Measured: Baseline, Day 98
Secondary outcomes (3)
Change From Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Score
Measured: Baseline, Day 98
Change From Baseline on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
Measured: Baseline, Day 98
Change From Baseline on the Clinical Global Impression-Severity Scale (CGI-S) Score
Measured: Baseline, Day 98
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jan 2022
- Study start7 Dec 2021
- Primary completion28 Jun 2024
- Study completion14 Oct 2024
Why it stopped: Failed to meet the primary endpoint
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- More trials run by Neurocrine BiosciencesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 216 participants (actual)
Sponsor and investigators
- Lead sponsor
- Neurocrine Biosciences
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Development Lead, Study director, Neurocrine Biosciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05182476
- Sponsor's protocol ID
- NBI-1065844-CIAS2023
- Other IDs
- 2021-003834-34
- Acronym
- ERUDITE
- Status last verified
- Dec 2024
- First submitted
- 17 Dec 2021
- Last updated
- 2 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Khin NA, Fan RH, Ge T, Klein HS, Ballon JS, Brar S, Harvey PD, Kantrowitz JT, Keefe RSE, Asgharnejad M, Murthy V, Roberts E, Singh JB. A phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE study. Neuropsychopharmacology. 2026 Apr 24. doi: 10.1038/s41386-026-02410-5. Online ahead of print.
PubMed 42032293
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia, Followed by Open-Label Treatment
- ClinicalTrials.gov ID
- NCT05182476
- Acronym / sponsor ID
- ERUDITE / NBI-1065844-CIAS2023
- Conditions
- Schizophrenia
- Keywords
- Schizophrenia, Cognitive Impairment, Luvadaxistat, NBI-1065844, TAK-831, CIAS, BAC, ERUDITE
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Failed to meet the primary endpoint
- Enrolment
- 216 participants (actual)
- Lead sponsor
- Neurocrine BiosciencesIndustry (pharma, biotech, devices)
- Study start
- 7 Dec 2021 (actual)
- Primary completion
- 28 Jun 2024 (actual)
- Study completion
- 14 Oct 2024 (actual)
- First posted
- 10 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in participants with schizophrenia.
Detailed description
A Phase 2, randomized, double-blind, parallel, placebo-controlled study with a 6- or 12-month open-label extension. The study is designed to evaluate the efficacy, safety and tolerability, and pharmacokinetics (PK) of treatment with luvadaxistat when administered orally once daily as an adjunctive treatment on improving symptoms of cognitive impairment associated with schizophrenia (CIAS).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboPlacebo daily |
| Luvadaxistat treatment schedule 1 | Experimental | Drug: LuvadaxistatLuvadaxistat daily |
| Luvadaxistat treatment schedule 2 | Experimental | Drug: LuvadaxistatLuvadaxistat daily |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Completed written informed consent.
- Participant must be 18 to 50 years of age (inclusive) and able to comply with all protocol procedures.
- Diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
- The initial diagnosis of schizophrenia must be ≥1 year before screening.
- The participant is currently receiving a stable regimen of psychotropic medications.
Key exclusion criteria (10 listed)
- Pregnant or breastfeeding or plans to become pregnant during the study.
- Exhibit more than a minimal level of extrapyramidal signs/symptoms.
- Schizophrenia diagnosis occurred before 12 years of age.
- Lifetime diagnosis of schizoaffective disorder, bipolar disorder, or obsessive-compulsive disorder.
- Recent occurrence of panic disorder, depressive episode, or other comorbid psychiatric conditions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboOral tablets | Drug | Placebo |
| LuvadaxistatAlso: NBI-1065844, TAK-831Oral tablets | Drug | Luvadaxistat treatment schedule 1, Luvadaxistat treatment schedule 2 |
Primary outcome
Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BAC) Composite Score
Time frame: Baseline, Day 98
3 secondary outcomes
Change From Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Score
Time frame: Baseline, Day 98
Change From Baseline on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
Time frame: Baseline, Day 98
Change From Baseline on the Clinical Global Impression-Severity Scale (CGI-S) Score
Time frame: Baseline, Day 98
Results and safety
The study was stopped early (reason given: Failed to meet the primary endpoint). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2025.
- Derived from this study: PubMed 42032293Khin NA, Fan RH, Ge T, Klein HS, Ballon JS, Brar S, Harvey PD, Kantrowitz JT, Keefe RSE, Asgharnejad M, Murthy V, Roberts E, Singh JB. A phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE study. Neuropsychopharmacology. 2026 Apr 24. doi: 10.1038/s41386-026-02410-5. Online ahead of print.
- Individual participant dataSharing planned: No
Related trials for Schizophrenia
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
Treatment Resistant Disorders
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Development Lead study director
Neurocrine Biosciences
49 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Luvadaxistat in people with Schizophrenia, run by Neurocrine Biosciences at 49 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 2 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 49 sites in United States, Bulgaria, Serbia, Czechia, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Failed to meet the primary endpoint). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BAC) Composite Score (time frame: Baseline, Day 98). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05182476, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2025.